


T 19002




(IV)

wherein

R^1 is lower alkyl, aryl or arylalkyl;

R^2 is hydrogen, hydroxy, alkoxy, $-CH_2OH$, cyano, $-C(O)OR^7$, $-CO_2H$, $-CONH_2$, tetrazole, $-CH_2NH_2$ or halogen;

R^3 is hydrogen, alkyl, heterocycle or



R^4 is hydrogen, alkyl or B;

R^5 , $R^{5'}$, R^8 , $R^{8'}$ and $R^{8''}$ are independently hydrogen, alkoxy, lower alkyl, halogen, $-OH$, $-CN$, $-(CH_2)_nNR^6COR^7$, $-CON(R^6)R^{6'}$, $-CON(R^6)OR^{6'}$, $-CO_2R^6$, $-SR^7$, $-SOR^7$, $-SO_2R^7$, $-N(R^6)SO_2R^1$, $-N(R^6)R^{6'}$, $-NR^6COR^7$, $-OCH_2CON(R^6)R^{6'}$, $-OCH_2CO_2R^7$ or aryl; or

R^5 and $R^{5'}$ or R^8 and $R^{8'}$ may together with the carbon atoms to which they are attached form an aryl or heterocycle;

R^6 and $R^{6'}$ are independently hydrogen or lower alkyl; and

R^7 is lower alkyl;

R^9 and $R^{9'}$ are independently hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or

R^9 and $R^{9'}$ may together with the nitrogen atom to which they are attached form a heterocycle;


A is a bond, $-(CH_2)_n-$ or $-CH(B)-$, wherein n is an integer of 1, 2 or 3 and

B is $-\text{CN}$, $-\text{CON}(\text{R}^9)\text{R}^9$ - or $-\text{CO}_2\text{R}^7$;

with the proviso that when A is a bond or $-(\text{CH}_2)_n-$ and R^3 is hydrogen or unsubstituted alkyl, then R^4 is B or substituted alkyl;

(b) a compound of formula (V) is represented by the following general formula:

wherein



n is 0 to 5;

m is 0 or 1;

r is 0 to 3;

A is pyridinyl;

R^1 is (1) hydroxy, (2) oxo, (3) halogen, (4) cyano, (5) NR^8R^8 , (6) SR^8 , (7) trifluoromethyl, (8) $\text{C}_1\text{-C}_{10}$ alkyl, (9) OR^8 , (10) SO_2R^9 , (11) OCOR^9 , (12) NR^8COR^9 , (13) COR^9 , (14) $\text{NR}^8\text{SO}_2\text{R}^9$, (15) $\text{NR}^8\text{CO}_2\text{R}^8$, or (16) $\text{C}_1\text{-C}_{10}$ alkyl substituted by hydroxy, halogen, cyano, NR^8R^8 , SR^8 , trifluoromethyl, OR^8 , $\text{C}_3\text{-C}_8$ cycloalkyl, phenyl, NR^8COR^9 , COR^9 , SO_2R^9 , OCOR^9 , $\text{NR}^8\text{SO}_2\text{R}^9$ or $\text{NR}^8\text{CO}_2\text{R}^8$;

R^2 and R^3 are independently (1) hydrogen, (2) $\text{C}_1\text{-C}_{10}$ alkyl or (3) $\text{C}_1\text{-C}_{10}$ alkyl with 1 to 4 substituents selected from hydroxy, $\text{C}_1\text{-C}_{10}$ alkoxy, or halogen;

X is (1) $-\text{CH}_2-$, (2) $-\text{CH}_2-$, (3) $-\text{CH}=\text{CH}-$ or (4) $-\text{CH}_2\text{O}-$;

R^4 and R^5 are independently (1) hydrogen, (2) $\text{C}_1\text{-C}_{10}$ alkyl, (3) halogen, (4) NHR^8 , (5) OR^8 , (6) SO_2R^9 or (7) NSO_2R^9 ;

R^6 is (1) hydrogen or (2) $\text{C}_1\text{-C}_{10}$ alkyl;

R^7 is $Z-(\text{R}^{1a})_n$;

R^{1a} is (1) R^1 , (2) $\text{C}_3\text{-C}_8$ cycloalkyl, (3) phenyl optionally substituted with up to 4 groups independently selected from R^8 , NR^8R^8 , OR^8 , SR^8 or halogen, or (4) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen, optionally

substituted with up to four groups independently selected from oxo, R⁸, NR⁸R⁸, OR⁸, SR⁸, or halogen;


Z is (1) phenyl, (2) naphthyl, (3) or a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen, (4) a benzene ring fused to a C₃-C₈ cycloalkyl ring, (5) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen, (6) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen, or (7) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen fused to a C₃-C₈ cycloalkyl ring;

R⁸ is (1) hydrogen, (2) C₁-C₁₀alkyl, (3) C₃-C₈ cycloalkyl, (4) Z optionally having 1 to 4 substituents selected from halogen, nitro, oxo, NR¹⁰R¹⁰, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₁-C₁₀ alkylthio, and C₁-C₁₀ alkyl having 1 to 4 substituents selected from hydroxy, halogen, CO₂H, CO₂-C₁-C₁₀ alkyl, SO₂-C₁-C₁₀ alkyl, C₃-C₈ cycloalkyl, C₁-C₁₀ alkoxy, or Z optionally substituted by from 1 to 3 halogen, C₁-C₁₀ alkyl or C₁-C₁₀ alkoxy, or (5) C₁-C₁₀ alkyl having 1 to 4 substituents selected from hydroxy, halogen, CO₂H, CO₂-C₁-C₁₀ alkyl, SO₂-C₁-C₁₀ alkyl, C₃-C₈ cycloalkyl, C₁-C₁₀ alkoxy, C₁-C₁₀ alkyl, or Z optionally substituted by from 1 to 4 halogen, C₁-C₁₀ alkyl or C₁-C₁₀ alkoxy;

R⁹ is (1) R⁸ or (2) NR⁸R⁸; and

R¹⁰ is (1) C₁-C₁₀ alkyl, or (2) two R¹⁰ groups together with the N to which they are attached forming a 5 or 6-membered ring optionally substituted with C₁-C₁₀ alkyl;

(c) a compound of formula (VI) is:




wherein

X is hydrogen, halogen, trifluoromethyl or lower alkyl, and

R is hydrogen; lower alkyl which may have a suitable substituent selected from the group consisting of cyclo(C₃-C₇)alkyl, hydroxy, lower alkoxy, carboxy and lower alkoxy carbonyl; cyclo(C₃-C₇)alkyl or lower alkanoyl;

(d) a compound of formula (VII) is represented by the following general formula:



wherein

R¹ is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group;

R² is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl group;

R³ is a hydrogen, chlorine or bromine atom or a hydroxyl group;

R⁴ is a hydrogen atom or a methyl group;

R⁵ is a hydrogen atom or a methyl group;


R⁶ is a hydrogen, fluorine or chlorine atom or a methyl, methoxyl or hydroxy group;

X is an oxygen atom or a bond;

Y is an alkylene group of up to 6 carbon atoms or a bond; and

Z is an alkylene, alkenylene or alkynylene group of up to 10 carbon atoms; and

(e) a compound of formula (VIII) is represented by the following general formula:



B1
wherein

R is hydrogen or methyl,

R¹ is hydrogen, halogen, hydroxy, benzyloxy, amino or hydroxymethyl,

R² is hydrogen, hydroxymethyl, -NHR³, -SO₂NR⁴R⁴ or nitro,

R³ is hydrogen, methyl, -SO₂R⁵, formyl or -CONHR⁶,

R⁴ and R⁴ are independently hydrogen, lower alkyl or benzyl,

R⁵ is lower alkyl, benzyl or -NR⁴R⁴,

R⁶ is hydrogen or lower alkyl,

R⁶ is hydrogen or lower alkyl,

R⁹ is hydrogen, amino, acetylamino or hydroxy, and

X is N, O, S or methylene;

provided that when X is N, O or S,

then R⁹ is hydrogen, either R⁷ or R⁸ is hydrogen, and the other is hydrogen, amino, acetylamino or hydroxy; and

provided that when X is methylene,

then both R⁷ and R⁸ are hydrogen.

B1 cont.
12. (Amended) The method of Claim 1Q comprising administering the compound of formula (IV) or a salt thereof.

B2
13. (Amended) The method of Claim 1Q comprising administering the compound of formula (VI) or a salt thereof.

14. (Amended) The method of Claim 1Q, comprising administering the compound of formula (VII) or a salt, ester or amide thereof.

15. (Amended) The method of Claim 1Q, comprising administering the compound of formula (VIII) or a salt thereof.

B3
16. A method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence comprising administering to a subject in need thereof an effective amount of the compound as defined in Claim 1Q or a pharmaceutically acceptable salt thereof.

17. (Amended) A method for the prophylactic and/or the therapeutic treatment of nervous pollakiuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic cystitis, chronic prostatitis, overflow incontinence, passive incontinence, reflex incontinence, urge incontinence, urinary stress incontinence comprising administering to a

subject in need thereof an effective amount of a compound as defined in Claim 10 or a pharmaceutically acceptable salt thereof.

(19) (Amended) A commercial package comprising:

the compound as defined in Claim 10 and

written matter associated therewith,

wherein the written matter states that the pharmaceutical composition can or should be used for preventing and/or treating dysuria.

(19) (Amended) An article of manufacture comprising:

a packaging material and

the compound as defined in Claim 10,

wherein said packaging material comprises a label or a written material which indicates that the compound defined in Claim 10 can or should be used for preventing and/or treating dysuria.--

Add new Claims 21-35:

21. (New) The method of Claim 10, comprising treating a subject having dysuria.

22. (New) The method of Claim 10, comprising treating a subject having pollakiuria.

23. (New) The method of Claim 10, comprising treating a subject having urinary incontinence.

24. (New) The method of Claim 10, comprising treating a subject having neurogenic bladder dysfunction.

25. (New) The method of Claim 10, comprising treating a subject having nervous pollakiuria.

26. (New) The method of Claim 10, comprising treating a subject having nocturia.

27. (New) The method of Claim 10, comprising treating a subject having an unstable bladder.

28. (New) The method of Claim 10, comprising treating a subject having cystospasm. *29.* (New) The method of Claim 10, comprising treating a subject having chronic cystitis.

30. (New) The method of Claim 10, comprising treating a subject having chronic prostatitis.